Osivax

Osivax

A clinical stage biotechnology company in France that focuses on developing a pipeline of vaccines and immunotherapies.

Osivax is a clinical stage biotechnology company in France that focuses on developing a pipeline of vaccines and immunotherapies. Founded 2017 in Lyon, Rhone-Alpes, France by Alexandre Levert and Florence Nicolas, Osivax has raised a total of €10.7M in funding over two rounds. Their latest funding was raised on July 10, 2019 from a Series A round. Osivax is funded by three investors, with Meusinvest (Noshaq) and Cédric Delorme as the most recent investors. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.

Timeline

July 8, 2020
Osivax raises a $2,212,389 grant from European Innovation Council.
July 8, 2020
Osivax raises a $13,274,336 series B round from European Innovation Council.
July 8, 2020
Osivax raises a $1,336,283 grant from Bpifrance.
July 10, 2019
Osivax raises a $7,142,857 series A round from Meusinvest and Anaxago.
June 15, 2017
Osivax raises a $2,410,714 seed round.
2017
Founded

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Osivax Seed round, June 2017
2,410,714
June 15, 2017
5 Results
Results per page:
Page 1 of 1

Products

Product
Launch date
Industry
Website
OVX836
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Florence Nicolas

​Chief Development Officer

Alexandre Levert

Founder and CEO

Fergal Hill

Chief Scientific Officer​

Paul Willems

Chief Medical Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Alex Keown
November 19, 2020
BioSpace
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Natalie Grover
November 13, 2020
the Guardian
'All of society is shutting down and thousands of people are dying ... so you need something on day one for next time.' Photograph: Andreas Gebert/Reuters
Natalie Grover
November 13, 2020
the Guardian
'All of society is shutting down and thousands of people are dying ... so you need something on day one for next time.' Photograph: Andreas Gebert/Reuters

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.